Skip to content
Brand AI

Sol-Gel Technologies

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2022

    Sol-Gel agrees to transfer rights to generic drug programs to Padagis

    Sol-Gel reported a new agreement with Padagis under which Sol-Gel would receive $21.5 million over 24 months in exchange for transferring its rights to two marketed generic drugs and eight unapproved generic programs. Sol-Gel would retain collaboration rights on two programs related to four high-value candidates.

    Source